Research programme: recombinant protein subunit vaccines - Hawaii Biotech

Drug Profile

Research programme: recombinant protein subunit vaccines - Hawaii Biotech

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hawaii Biotech
  • Class Parasitic vaccines; Recombinant proteins; Subunit vaccines; Viral envelope proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection
  • No development reported Crimean-Congo haemorrhagic fever virus infections; Encephalitis virus infections; Malaria

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for research development in Crimean-Congo-haemorrhagic-fever-virus-infections in USA (Parenteral)
  • 30 Aug 2016 Hawaii Biotech receives SBIR grant from National Institute of Allergy and Infectious Disease (NIAID) for vaccine development in Chikungunya
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top